Walleye Capital
ALXN

Walleye Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Walleye Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-66,350
Closed -$12.2K – 2067
2021
Q2 		$12.2K Buy
66,350
+25,983
+64% +$4.46M 0.45% 16
2021
Q1 		$6.17K Buy
40,367
+7,614
+23% +$1.18M 0.39% 37
2020
Q4 		$5.12K Buy
32,753
+30,332
+1,253% +$3.9M 0.39% 37
2020
Q3 		$277K Buy
+2,421
New +$261K 0.03% 522
2020
Q2 		– Sell
-15,446
Closed -$1.39M – 1175
2020
Q1 		$1.39M Sell
15,446
-2,960
-16% -$291K 0.42% 89
2019
Q4 		$1.99M Buy
18,406
+17,347
+1,638% +$1.86M 0.44% 199
2019
Q3 		$103K Buy
1,059
+859
+430% +$96.8K 0.07% 1431
2019
Q2 		$26K Hold
200
– – 0.03% 1495
2019
Q1 		$27K Buy
+200
New +$24.9K 0.04% 1315
2018
Q3 		$295K Buy
+2,125
New +$267K 0.16% 178

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return